Geron Corporation (GERN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Geron Corporation (GERN) has a cash flow conversion efficiency ratio of -0.072x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-15.83 Million) by net assets ($218.61 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see GERN stock market capitalisation for the company's overall valuation and market capitalisation.
Geron Corporation - Cash Flow Conversion Efficiency Trend (1996–2025)
This chart illustrates how Geron Corporation's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Geron Corporation Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Geron Corporation ranked by their cash flow conversion efficiency. Explore GERN operating cash flow to net income to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Wuxi Longsheng Technology Co Ltd
SHE:300680
|
0.055x |
|
Chengdu Guibao Science Tech
SHE:300019
|
0.077x |
|
Besalco Sa
SN:BESALCO
|
0.062x |
|
XiAn ChenXi Aviation Technology Corp Ltd
SHE:300581
|
-0.005x |
|
WCON Electronics (Guangdong) Co. Ltd. A
SHE:301328
|
N/A |
|
Theravance Biopharma Inc
F:0TB
|
-0.028x |
|
Heritage Commerce Corp
NASDAQ:HTBK
|
0.028x |
|
Compass Diversified Holdings
NYSE:CODI
|
0.049x |
Annual Cash Flow Conversion Efficiency for Geron Corporation (1996–2025)
The table below shows the annual cash flow conversion efficiency of Geron Corporation from 1996 to 2025. View Geron Corporation stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $225.87 Million | $-111.04 Million | -0.492x | +36.97% |
| 2024-12-31 | $280.32 Million | $-218.62 Million | -0.780x | -15.28% |
| 2023-12-31 | $247.95 Million | $-167.74 Million | -0.677x | +57.51% |
| 2022-12-31 | $80.00 Million | $-127.38 Million | -1.592x | -110.65% |
| 2021-12-31 | $126.42 Million | $-95.56 Million | -0.756x | -139.23% |
| 2020-12-31 | $210.95 Million | $-66.65 Million | -0.316x | +2.57% |
| 2019-12-31 | $135.16 Million | $-43.83 Million | -0.324x | -174.34% |
| 2018-12-31 | $177.73 Million | $-21.01 Million | -0.118x | +40.31% |
| 2017-12-31 | $103.80 Million | $-20.56 Million | -0.198x | -31.94% |
| 2016-12-31 | $122.38 Million | $-18.37 Million | -0.150x | +11.83% |
| 2015-12-31 | $142.13 Million | $-24.20 Million | -0.170x | -338.00% |
| 2014-12-31 | $130.71 Million | $9.35 Million | 0.072x | +111.65% |
| 2013-12-31 | $59.76 Million | $-36.68 Million | -0.614x | +4.66% |
| 2012-12-31 | $85.65 Million | $-55.15 Million | -0.644x | -51.28% |
| 2011-12-31 | $146.60 Million | $-62.39 Million | -0.426x | -85.19% |
| 2010-12-31 | $192.74 Million | $-44.29 Million | -0.230x | +8.56% |
| 2009-12-31 | $172.58 Million | $-43.37 Million | -0.251x | -0.84% |
| 2008-12-31 | $168.46 Million | $-41.98 Million | -0.249x | -92.48% |
| 2007-12-31 | $205.67 Million | $-26.63 Million | -0.129x | +14.63% |
| 2006-12-31 | $173.92 Million | $-26.38 Million | -0.152x | -40.32% |
| 2005-12-31 | $190.71 Million | $-20.61 Million | -0.108x | +49.11% |
| 2004-12-31 | $122.06 Million | $-25.93 Million | -0.212x | +7.43% |
| 2003-12-31 | $106.32 Million | $-24.40 Million | -0.229x | +78.23% |
| 2002-12-31 | $29.74 Million | $-31.34 Million | -1.054x | -189.24% |
| 2001-12-31 | $61.54 Million | $-22.42 Million | -0.364x | -71.18% |
| 2000-12-31 | $63.92 Million | $-13.61 Million | -0.213x | +58.99% |
| 1999-12-31 | $26.20 Million | $-13.60 Million | -0.519x | -118.28% |
| 1998-12-31 | $32.80 Million | $-7.80 Million | -0.238x | +36.49% |
| 1997-12-31 | $21.10 Million | $-7.90 Million | -0.374x | +10.75% |
| 1996-12-31 | $23.60 Million | $-9.90 Million | -0.419x | -- |
About Geron Corporation
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lowe… Read more